Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are mast cells all bad?

C P Page1

  • 1Department of Pharmacology, King's College, University of London, UK.

Postgraduate Medical Journal
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Beta 2 agonists, used for asthma, may paradoxically increase disease severity by inhibiting natural anti-inflammatory mast cell responses. This challenges current asthma treatment strategies and explains rising morbidity and mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic Interactions Between the Quinolone-Derived Compound HT61 and Tobramycin Against a Range of Clinical Isolates of Pseudomonas aeruginosa In Vitro.

Lung·2025
Same author

A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin.

Journal of pharmacological and toxicological methods·2021
Same author

The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.

Pulmonary pharmacology & therapeutics·2019
Same author

Pharmacology and Therapeutics of Bronchodilators Revisited.

Pharmacological reviews·2019
Same author

Radiolabelling and immunohistochemistry reveal platelet recruitment into lungs and platelet migration into airspaces following LPS inhalation in mice.

Journal of pharmacological and toxicological methods·2019
Same author

Use of animal models in IPF research.

Pulmonary pharmacology & therapeutics·2018
Same journal

Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

Postgraduate medical journal·2026
Same journal

Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

Postgraduate medical journal·2026
Same journal

Care, cash, and proof: forensic accountability for war-related starvation.

Postgraduate medical journal·2026
Same journal

Response to traumatic injuries in polo players in England.

Postgraduate medical journal·2026
Same journal

Aids to venesection and parenteral drug administration in patients with difficult veins.

Postgraduate medical journal·2026
Same journal

Diagnostic reasoning in clinical neurology: a comprehensive primer.

Postgraduate medical journal·2026
See all related articles

Area of Science:

  • Pulmonology
  • Pharmacology
  • Immunology

Background:

  • Asthma pathogenesis understanding has advanced, with new therapies developed.
  • Despite advances, asthma morbidity and mortality continue to rise globally.
  • A paradox exists between increased knowledge/therapy and worsening asthma outcomes.

Purpose of the Study:

  • To explain the paradox of increasing asthma morbidity and mortality despite advances.
  • To investigate a potential pharmacological mechanism of beta 2 agonists contributing to this paradox.

Main Methods:

  • Review of pharmacological effects of beta 2 agonists.
  • Analysis of the role of mast cell degranulation in asthma.
  • Hypothesizing the link between beta 2 agonist action and mast cell inhibition.

Related Experiment Videos

Main Results:

  • Beta 2 agonists, widely used for asthma, possess a known effect of inhibiting mast cell degranulation.
  • This inhibition may counteract a natural anti-inflammatory pathway mediated by mast cell products.

Conclusions:

  • Beta 2 agonists might inadvertently promote asthma inflammation and severity by suppressing mast cell anti-inflammatory functions.
  • This mechanism offers a plausible explanation for the persistent increase in global asthma morbidity and mortality.
  • Re-evaluation of asthma treatment strategies involving beta 2 agonists may be warranted.